Axiall – Something Else Up Its Sleeve?
Axiall’s apparent reluctance to engage with Westlake in a formal discussion with respect to Westlake’s offer (resulting in a higher bid from Westlake this morning) suggests one of two possible positions:
- Axiall believes that it can win a proxy battle and continue with business as usual
- Axiall has another bidder – a better offer – and is ironing out the details
Option 1 would be a huge tactical error in our opinion and would suggest that Axiall is not listening to its shareholders and at the same time is a poor student of very recent history.
- Our conversations with many investors suggest that all favor a deal with Westlake, or someone else, and a strong leaning towards voting for Westlake’s slate of board members in the coming shareholder meeting.
- Those shareholders who did not vote in favor of Trian’s plan for DuPont in May of last year saw an immediate 8% decline in the stock and a subsequent 35% decline in the stock as the company continued to disappoint on earnings.
- This resulted in the board finally making the decision to remove the CEO, something Trian was not looking for – the company just wanted a board seat.
- It is unlikely that shareholders of Axiall will follow the same path that shareholders of DuPont did last May given that clear lesson. There is no debate around whether the PVC/chlor-alkali markets need consolidation and a Westlake/Axiall combination is strategically optimal.
Any new director slate at Axiall would have the same fiduciary responsibility as the current slate, but they will approve a formal sit down with Westlake and the two companies can establish a better view of possible synergies and a fair price. OF COURSE THIS OPTION IS OPEN TO AXIALL TODAY AND THE NEW OFFER SHOULD PROMOTE DISCUSSION – as a board of directors why wait and risk the extreme embarrassment of being voted off the board en-masse… unless…
Option 2 – There is someone else. This would be the only face saving move for Axiall in our view and it would need to be a good offer – either in cash, or in stock from someone who can pull out as much synergy as Westlake.
The only companies who could pull out the synergies to the maximum would be existing PVC players and we do not think that either Oxy or Mexichem would be interested and both ShinEtsu and Formosa are busy investing in ethylene already. Ineos is the only logical consolidator in our view – this would have to be all cash.
The second group are those with too much ethylene in the US – Lyondell, Shell, Williams (and possibly Ineos again). With the exception of Ineos we do not see any of these companies interested in jumping into PVC.
The third group are non US players wanting a US foothold. Lotte already has this with the ethylene venture (regardless of the eventual partner); Indorama has a toe hold through the PTA/polyester chain; Reliance and any number of possible Chinese companies (given the move that Chem China just made) are most likely to take a look.
We think that the Axiall team and its advisors must know that playing this out through the proxy process is a long odds and potentially embarrassing path to take – consequently we believe that there is a deal in the wings and if it does not come off soon, the company will engage with Westlake. Regardless, we would own the stock even with the increase today – we believe in higher synergies than are implied in the revised offer though much of the upside is likely gone with this offer.
©2016, SSR LLC, 1055 Washington Blvd, Stamford, CT 06901. All rights reserved. The information contained in this report has been obtained from sources believed to be reliable, and its accuracy and completeness is not guaranteed. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained herein. The views and other information provided are subject to change without notice. This report is issued without regard to the specific investment objectives, financial situation or particular needs of any specific recipient and is not construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not necessarily a guide to future results.